Floatz logo

Crizotinib

Anaplastic Lymphoma Kinase Gene Translocation

Massachusetts General HospitalSmall moleculePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Anaplastic Lymphoma Kinase Gene Translocation cohort.

Asset / SponsorPhaseRating
ALECTINIB
University Medical Center Groningen
Phase 4BB
Binimetinib
Massachusetts General Hospital
Phase 1/2CCC
Lorlatinib
Massachusetts General Hospital
Phase 1/2CCC
tno155
Massachusetts General Hospital
Phase 1/2CC

Same molecule, other indications

Crizotinib is also rated in:

anaplastic large cell lymphomaDormant
BBB
Indicative ·
75 / 100
View asset →
inflammatory myofibroblastic tumorDormant
BB
Indicative ·
69 / 100
View asset →
ALK-positive anaplastic large cell lymphomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →